AMPH
AmphastarDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bullish read is that the quarter showed commercial support from newer products and the Ipratropium Bromide HFA launch, while the stock's sharp post-earnings decline leaves room for recovery if margin pressure proves transitory and newer products continue scaling.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Glucagon revenue fell 56% and BAQSIMI revenue fell 15%, showing ongoing competition and unfavorable gross-to-net dynamics in important products.
Momentum
8
Value
71
Sentiment
65
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $22.00 · Bull $27.00 · Bear $16.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $29.00
Why
Momentum8 · Δ7d +0.6
Value71 · Δ7d +0.2
Sentiment65 · Δ7d +3.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
8
34% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
-16.8
Value
71
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.2
Sentiment
65
33% active weight
Current posture
7d trendImproving
Δ7d
+3.3
Δ21d
+8.9
Why this grade
Composite grade D. Momentum 8.3 / Value 71.3 / Sentiment 65.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$812.19M
Beta
0.87
Shares Out
45.95M
P/E (TTM)
11.8
P/S (TTM)
1.70
P/FCF (TTM)
11.06
Rev YoY
+0.3%
EPS YoY
-53.3%
Gross Margin
+49.4%
Op Margin
+20.7%
Net Debt
$380.22M
Current Ratio
3.12
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology